Met exon 14 skipping in non-small cell lung cancer

Oncologist

Volumn 21, Issue 4, 2016, Pages 481-486

  Heist, Rebecca S ^a   Shim, Hyo Sup ^a,b   Gingipally, Shalini ^a   Mino Kenudson, Mari ^a   Le, Long ^a   Gainor, Justin F ^a   Zheng, Zongli ^a   Aryee, Martin ^a   Xia, Junfeng ^c,d   Jia, Peilin ^d   Jin, Hailing ^d   Zhao, Zhongming ^d,e   Pao, William ^d   Engelman, Jeffrey A ^a   Iafrate, A John ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c ANHUI UNIVERSITY   (China)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Lung cancer; MET exon 14 skipping; Targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CATENIN CADHERIN ASSOCIATED PROTEIN BETA; CRIZOTINIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; ROS1 PROTEIN; SMAD4 PROTEIN; UNCLASSIFIED DRUG; MET PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR;

AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; ENDARTERECTOMY; EXON SKIPPING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; MALE; MET EXON 14 MUTATION; MULTIPLEX POLYMERASE CHAIN REACTION; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; RNA EXTRACTION; SMOKING; SQUAMOUS CELL CARCINOMA; VERY ELDERLY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; EXON; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; FEMALE; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-MET; SMOKING;

EID: 84963865419     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0510     Document Type: Article

References (27)

1. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer togefitinib. NEngl JMed2004;350:2129-2139.
2. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
3. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
4. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
5. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448: 561-566.
6. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
7. Shaw AT, Kim DW, Mehra Ret al. Ceritinib in AL Krearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-1197.
8. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1- rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-1971.
9. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-1075.
10. Seo JS, Ju YS, Lee WC et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012;22:2109-2119.
11. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-550.
12. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-525.
13. Dias-Santagata D, Akhavanfard S, David SS et al. Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBOMol Med 2010;2:146-158.
14. Sequist LV, Heist RS, Shaw AT et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22:2616-2624.
15. Zheng Z, Liebers M, Zhelyazkova B et al. Anchored multiplex PCR for targeted nextgeneration sequencing. Nat Med 2014;20: 1479-1484.
16. Kong-Beltran M, Seshagiri S, Zha J et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283-289.
17. Ma PC, Jagadeeswaran R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interferingRNAin non-small cell lung cancer. Cancer Res 2005;65:1479-1488.
18. Frampton GM, Ali SM, Rosenzweig M et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5:850-859.
19. Onozato R, Kosaka T, Kuwano H et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009;4:5-11.
20. Awad MM, Oxnard GR, Jackman DM et al. MET exon 14 mutations in nonsmall cell lung cancer are associated with advanced age and stage dependent MET genomic amplification and c-met overexpression. J Clin Oncol 2016 [Epub ahead of print].
21. Liu X, Jia Y, Stooper MB et al. Next generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency actionable MET gene mutations. J Clin Oncol 2015 [Epub ahead of print]
22. Paik PK, Drilon A, Fan PD et al. Responseto MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5:842-849.
23. Tanizaki J, Okamoto I, Okamoto K et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 2011;6:1624-1631.
24. Matsubara D, Ishikawa S, Oguni S et al. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J Thorac Oncol 2010;5:1317-1324.
25. Mendenhall MA, Goldman JW. MET-mutated NSCLC with major response to crizotinib. J Thorac Oncol 2015;10:e33-e34.
26. Waqar SN, Morgensztern D, Sehn J. MET mutation associated with responsiveness to crizotinib. J Thorac Oncol 2015;10:e29-e31.
27. Jenkins RW, Oxnard GR, Elkin S et al. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin Lun Cancer 2015;6:e101-104.